NATCO PHARMA LTD. was incorporated on 19th September, 1981 in Andhra Pradesh as a Pvt. Ltd. Company as NATCO FINE PHARMACEUTICALS P. LTD. and became a deemed Public Company with effect from 1st July, 1992 under Section 43A of the Act. Subsequently, it changed its name to NATCO PHARMA LTD. on 18th February, 1993 and received change of name certificate. The Company began operations in 1984 with an objective to manufacture conventional and Timed Release Dosage forms of life savings drugs. The company's factory is located 35km. away from Hyderabad on Bangalore Highway No. 7. to manufacture a wide range of tablets, capsules, liquids and dry powders using automated equipments Indigenisation of Microdialysis Cell technology for various dosage forms was taken up as a challenge and Company had introduced Antihistaminic, Antianxiety, Antiasthmatic, Cardiac Drugs into Indian Market for the first time in sustained action dosage forms. The major products manufactured by the company are as follows: FLOCY (CIPROFLOXACIN HCI), NATCOCILLIN (AMPICILLIN), NATAMOX (AMOXYCILLIN), TR PHYLLIN (THEOPHYLLINE), BETACAP TR (PROPRANOLOL HCI), CARDICAP TR (ISOSORBIDE-Dl-NlTRATE), IBUBID TR (IBUPROFEN), NACLO TR (DICLOFENAC SODIUM), CAMRELEASE TR (DIAZEPAM), CEPIAM TR (CHLORPHENIRAMINE MALEATE), POTRELEASE TR (POTASSIUM CHLORIDE), COLDACT (PHENYL PROPANOLAMINE) HCI CHLORPHENlRAMINE MALEATE) The Company holds the necessary licences issued by the Drug Control Authorities for the manufacture of these drugs at its existing plant at Kothur, Mahaboobnagar. The turnover of the unit increased progressively; the turnover which was at Rs. 730 lacs for the year 1989-90 has grown to Rs. 3689.24 Lacs for the year 1993-94. The Company has pioneered Timed Release Technology in India by introducing Multi-unit, Multi-layered System for the first time in India in the year 1985. The company's formulation Rubinat is ranked second in the Anticancer Drug Segment and first in the Anthracyclines Segment on the basis of turnover of 1993-94. The Company has been awarded Import Substitution Award (1986) for Timed Release Technology. It has well equipped Research and Development facilities manned by qualified Scientists. Its formulations are exported to the CIS States, Vietnam, Hongkong, China, Netherlands, Nigeria, Tanzania and Kenya. The Annual average exports sales for the last three years is 21% of turnover. The Export turnover details for last 3 years are as follows: (Rs. in lakhs) ----------------------------------------------------- Year Total Export % to Total Turnover Turnover ----------------------------------------------------- 1991-92 1169.36 47.39 4% 1992-93 2840.00 739.86 26% 1993-94 3542.74 1168.64 33% Sept. '94 3402.59 1740.15 51% (6 months) ----------------------------------------------------- The Company is a recipient of WHO Certificate for maintaining good manutacturing practices. The Company is one of the contract manufacturers in the pharmaceuticals industry in India and manufactures products for companies including Ranbaxy Laboratories Ltd., Eskayef Ltd., Parke Davis (I) Ltd., Fulford India Limited, Cadila Ltd., John Wyeth India Ltd., ICI Ltd. and SOL Pharmaceuticals Ltd. 1996 -Natco Pharma (NPL) was promoted by V C Nannapaneni an NRI based in the US for 13 years. -Launches the anti-migraine Sumatriptan Succinate under the brand name Suminat. -Awarded an export house status by the Directorate General of Foreign trade Ministry of Commerce 1997 -Natco Pharma Limited have entered into an agreement giving the former business rights for Natco's products in Russia and other CIS countries. -Natco Pharma (NPL) has achieved the status of "the complete pharma company" on the merger of its four group companies - Natco Pharma Natco Laboratories Natco Parenterals and Dr.Karanth Pharma Chemical Labs - effective 1 Apr.'95. -Natco Pharma (NPL) was promoted in 1983 by V C Nannapaneni an NRI who had worked in the US for 13 years. 1998 -Natco Pharma Ltd has tied up with the US pharmaceutical giant Mallin Krodt for exporting in high volume production of naproxen. 2000 -The Executive Director Dr. K.V. Ranga Rao has resigned but continues in the capacity of a director. 2001 -Entered into the formulations segment by recently introducing 34 products in the state. -The company allotted 42,70 ,500 No. of equity shares at Rs. 17 each on preferential basis. 2002 -Natco Pharma has been given a revamping package from IDBI -Dr. Mohana R Velagapudi, Dr. K V Ranga Rao and Dr. N Ramakrishna Rao have resigned from the Board w.e.f. March 31, 2002. -Board Approves the preferential offer of Rs 6.6 crore equity warrants to its promoters group and Rs 6 crore 12 per cent cumulative redeemable preference shares to FIs and banks. -Natco Pharma Ltd, has received the approval from Therapeutic Goods Administration (TGA), Australia for its manufacturing facility at Mekaguda in Mehabobnagar. -Board inducted in to the Audit Committee Dr. K U Mada as a member. The Board constituted the Remuneration Committee with the following members: 1) Dr. K U Mada, 2) Mr. Jahar Bhowmik, 3) Mr. R Monani, 4) M. G S Murthy. 2003 -Launches the anti-cancer wonder drug under the brand name VEENAT (Imatinib 100mg capsules) -A city pharma company has filed a criminal complaint about `theft' of some of its technologies by a senior executive responsible for technology management of its products - launched Zoldonat Zoledronic Acid for injection. With this launch, NATCO has become the second company to launch Zoledronic Acid in the world, after Novartis, the patent holders. -Launches Letronat 2.5 mg tablets (Latrozole tablets). Letrozole, the non-sterioidal aromatase inhibitor is indicated for first-line treatment of advanced breast cancer in postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. -Received an order Rs 35-fr for export of citalopram hydrobromide (which is used for the treatment as an anti-depressant) for regulated markets and imatinibmesylate (used for the treatmemt of chronic myeloid leukaemia) -Following shareholders have sold shares in the company: 1) VC Nannapaneni - 90,000 shares, 2) Time Cap Pharma Labs Pvt. Ltd. - 2,80,000 shares. -Received a letter from Mr. V. C. Nannapaneni, one of the share holders informing the Company that he has sold 3,32,554 shares and that his post sale holding is 49,65,346 shares (28.57% of the paid up capital). - An award has being presented titled as "DSIR National Award for R&D efforts in the Industry (2003)" under the Dept. of Scientific and Industrial Research, Ministry of Science and Technology, Govt. of India. - Mr Rajeev Nannapaneni has been appointed as new Chief Operating Officer of the Company w.e.f December 1, 2003. -Promoters offload shares to raise funds -Unveils new drug for brain tumour therapy, Temozolomide under the brand name `Temonat' indicated for treatment of certain forms of brain tumours. -Launches Geftinib 250 mg., an anti-cancer drug, under the brand name "GEFTINAT" 2004 -Natco Pharma Limited has informed that the sad and sudden demise of Mr. Raj Monani, one of the Company's Board of Directors -Natco Pharma Ltd has informed the that the company has launched Ganciclovir in 250 mg. capsules and 500 ml injection forms -Natco Launches anti Cancer Drug, establishes Oncology division -Natco Pharma Ltd, the Hyderabad-based pharmaceutical company known for its timed-release technology and affordable drugs in cancer therapy, has bagged the award from the Indian Red Cross Society of Chennai -NATCO launches drug to treat prostate cancer -NATCO launches drug for Ovarian Cancer -Launches Curcumin 500 mg capsules under the brand name Turcumin 2005 - Receives Certification of Suitability of Monographs of the European Pharmacopoeia for its active pharmaceutical ingredients - Ondansetron Hydrochloride Dihydrate and Sumatriptan Succinate by European Directorate for the Quantity of Medicines (EDQM). -Natco Pharma Limited signs memorandum of understanding (MoU) for sharing technology related to manufacture of oncology products. -Natco Pharma launches anti-migraine drug -Natco Pharma ties up with Temple University, USA -Natco Pharma launches Vorizol 2006 -Natco announces launch of Pemnat (Pemetrexed) for treatment of non-small cell lung cancer 2007 -Natco Pharma Ltd has announced the launch of a world class oral contraceptive under the brand name Tarana. 2009 - Natco Pharma Ltd ties up with Dr. Reddy's for oncological products. 2010 -Natco Pharma - Natco launches BENDIT(Bendamustine). -Natco Pharma - NATCO launches Anastrazole in the USA. 2011 -"NATCO's new chemical entity (NCE) receives 'Orphan' designation from, US FDA". -"Natco files ANDA for generic Tykerb, Ties up with Lupin Limited". -NATCO and Levomed LLC, USA formed a Joint Venture company, NATCOFARMA DO BRASIL for sales and distribution in Brazil. 2012 -"Golden Peacock Award for Corporate Social Responsibility - 2012". -NATCO Pharma receives approval for Lansoprazole capsules. 2013 -Natco Pharma gets marketing approval for Rizatriptan Benzoate tablets orally disintegrating 5 mg and 10 mg. Used for the treatment of migraine headaches with or without aura. -Natco Pharma hits 52-week high on getting US Court nod for generic Copaxone used for treating multiple sclerosis. -Natco Pharma zooms over 11% on winning cancer drug case 2014 -"Natco's Kothur Formulation Facility found acceptable by USFDA". -Natco Pharma gets USFDA nod for Oseltamivir Phosphate Capsules. - Natco Pharma announced that it's marketing partner in the USA, Breckenridge Pharmaceuticals, Inc. (BPI), has filed an Abbreviated New Drug Application (ANDA) for its Everolimus 0.25 mg, 0.5 mg and 0.75 mg tablets. 2015 -Natco launches HEPCINAT LP in Nepal -Natco received the Best Speciality Brand-SILVER AWARD" for marketing excellence in India -Natco Pharma Limited, Winner Of ` Golden Peacock Innovation Management Award' For The Year 2015 -Natco launches HEPCINAT in Nepal- 1 st generic version of Sofosbuvir (Sovaldir) in the country -Natco Pharma has splits its face value from Rs. 10 to Rs. 2 2016 - Natco Launches the First Generic equivalent of Tamiflur Capsules in the USA Market 2017 -"NATCO launches VELPANAT in Nepal- 1st generic version of Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination medicine in the country". -Winner of "Golden Peacock Occupational Health and Safety Award" for the Year 2017. - 'NATCO's partner Mylan Wins U.S. District Court Ruling Related to Copaxone 40 mg/mL Patents". -NATCO launches POMALID, first generic version of pomalidomide capsules, for treatment of a specific blood cancer, in INDIA. -"Natco & its alliance partner Lupin receive FDA approval forgeneric Lanthanum Carbonate Chewable Tablets". -Winner of "Golden Peacock Innovation Management Award" for the year 2017. -"NATCO's marketing partner Mylan launches generic Glatiramer Acetate in the U.S. market - both20 mg/mL and 40 mg/mL versions" -Natco's marketing partner Alvogen first to market generic equivalent to oseltamivir phosphate powder for oral suspension in the USA -"NATCO launches TAFNAT, Tenofovir Alafenamide tablets, for treatment of chronic hepatitis B, in INDIA". -Natco & it's Chairman, Mr. VC Nannapaneni win India's Greatest Brands and Leaders 2016-17 awards at the Second Edition of India's Greatest Brands and Leaders 2017 organised by URS-AsiaOne magazine and UWG Media Consulting P.L. 2018 -NATCO launches fixed dose combination of Sofosbuvir-Daclatasvir drug for Hepatitis C treatment in INDIA. -NATCO launches generic Posaconazole Injection- 1st time available in INDIA. -Natco Pharma Limited announced today that it is the first company in India to launch a generic version of Teriflunomide, for the treatment of Relapsing and Remitting forms of Multiple Sclerosis (RRMS), under its brand DENOPSY. -NATCO announces USFDA filing for Sofosbuvir tablets, 400 mg. -USFDA completes inspection of Natco's Mekaguda API facility with zero observations in Mekaguda Village, near Hyderabad, India. 2019 -USFDA completes inspection of NATCO's Mekaguda active pharmaceutical ingredient facility. -Natco's marketing partner Alvogen receives FDA approval for Nitroglycerin Sublingual Tablets -Natco & its alliance partner Lupin receive FDA approval for generic Bosentan Tablets. -NATCO and Alvogen file ANDA for Ibrutinib Tablets for the USA market. -NATCO launches Valsartan-Sacubitril tablet in INDIA at an affordable price, under its brand VALSAC. 2020 -NATCO announces launch of breast cancer medicine Lapatinib Tablets in the U.S. -NATCO supports Columbia University's clinical trial of chloroquine phosphate to prevent symptomatic Covid-19 infections. -NATCO receives establishment inspection report (EIR) for Kothur's formulation facility . -NATCO's Vizag formulation facility receives USFDA approval. 2021 -NATCO launches Tipanat tablets in India, for the treatment of advanced colorectal and gastric cancer. -NATCO announces launch of its 10mg strength for Everolimus Tablets (generic for Afinitorr) in the US market. -Natco Pharma (Canada) Inc. announces the launch of PrNAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid. -NATCO receives approval for Carfilzomib Vials ANDA (generic for KYPROLISr ) in the US market. -NATCO signs Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India. -NATCO receives final approval for Everolimus tablets (generic for Afinitorr) for the US market 2022 -NATCO Launches Chlorantraniliprole (CTPR) Product NATGEN. -Natco Pharma signs license agreement with Medicines Patent Pool, Switzerland. -NATCO Pharma Limited has been awarded Corporate Governance Award. -"NATCO completes acquisition of Dash Pharmaceuticals LLC". 2023 -NATCO launched generic Pomalidomide Capsules in Canada. -NATCO received final approval for Tipiracil Hydrochloride and Trifluridine (generic for Lonsurf) for the US market. 2024 -NATCO's partner Mylan settles patent litigation with Novo Nordisk over generic Ozempic in US -